drugset / Trial / NCT06841965
Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer
Phase 3
Not yet recruiting
280 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary hypothesis being tested in this trial is that ischemic stroke patients with active cancer will have improved clinical outcomes when given intravenous thrombolysis compared to standard care.
Timeline
- Start
- 2025-03-01
- Primary completion
- 2027-06-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alteplase | Protein / enzyme biologic | 0.9 mg/kg | Intravenous |
| Subject | Tenecteplase | Protein / enzyme biologic | 0.25 mg/kg | Intravenous |
| Subject | prourokinase | Protein / enzyme biologic | 20 mg | Intravenous |
| Subject | reteplase | Protein / enzyme biologic | 18 mg | Intravenous |